| Literature DB >> 16341085 |
D J Hunter, E Riboli, C A Haiman, D Albanes, D Altshuler, S J Chanock, R B Haynes, B E Henderson, R Kaaks, D O Stram, G Thomas, M J Thun, H Blanché, J E Buring, N P Burtt, E E Calle, H Cann, F Canzian, Y C Chen, G A Colditz, D G Cox, A M Dunning, H S Feigelson, M L Freedman, J M Gaziano, E Giovannucci, S E Hankinson, J N Hirschhorn, R N Hoover, T Key, L N Kolonel, P Kraft, L Le Marchand, S Liu, J Ma, S Melnick, P Pharaoh, M C Pike, C Rodriguez, V W Setiawan, M J Stampfer, E Trapido, R Travis, J Virtamo, S Wacholder, W C Willett.
Abstract
Most cases of breast and prostate cancer are not associated with mutations in known high-penetrance genes, indicating the involvement of multiple low-penetrance risk alleles. Studies that have attempted to identify these genes have met with limited success. The National Cancer Institute Breast and Prostate Cancer Cohort Consortium--a pooled analysis of multiple large cohort studies with a total of more than 5,000 cases of breast cancer and 8,000 cases of prostate cancer--was therefore initiated. The goal of this consortium is to characterize variations in approximately 50 genes that mediate two pathways that are associated with these cancers--the steroid-hormone metabolism pathway and the insulin-like growth factor signalling pathway--and to associate these variations with cancer risk.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16341085 DOI： 10.1038/nrc1754
Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716